

Charles F. Kettring prize. Fundamental studies with cisplatin

Cancer

55, 2303-2316

DOI: 10.1002/1097-0142(19850515)55:10<2303::aid-cnrcr2820551002>3.0.co;2-l

Citation Report

#	ARTICLE	IF	CITATIONS
1	Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice. <i>Chemico-Biological Interactions</i> , 1985, 56, 45-54.	1.7	21
2	Spin-Label Substitutions in Cisplatin Reduce Toxicity and Interaction with Radiation. <i>Radiation Research</i> , 1986, 106, 141.	0.7	8
3	Intravesical Chemotherapy: Studies on the Relationship between Osmolality and Cytotoxicity. <i>Journal of Urology</i> , 1986, 136, 399-402.	0.2	11
4	Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 8923-8925.	3.3	344
5	Formation and Characterization of Cisplatin Loaded Poly(d,l-Lactide) Microspheres for Chemoembolization. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 750-755.	1.6	129
6	Invited review: Invasive Bladder cancer?Possible future treatment considerations. <i>Urological Research</i> , 1986, 14, 191-194.	1.5	1
7	Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: A phase II study. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 657-661.	0.9	8
8	Cisplatin and Radiotherapy in the Treatment of Unresectable Lung Cancer. <i>Tumori</i> , 1987, 73, 623-625.	0.6	2
9	High-dose carboplatin in refractory ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 1987, 5, 197-201.	0.8	155
10	Ovarian cancer. <i>Current Problems in Cancer</i> , 1987, 11, 61-122.	1.0	51
11	Cancer risk from inorganics. <i>Cancer and Metastasis Reviews</i> , 1987, 6, 113-154.	2.7	43
12	Genotoxic effects of cisplatin in somatic tissue of <i>Drosophila melanogaster</i> . <i>Environmental and Molecular Mutagenesis</i> , 1987, 10, 197-203.	0.9	18
13	Therapeutic efficacy of various dosages and modalities of administration. <i>Inorganica Chimica Acta</i> , 1987, 137, 91-97.	1.2	4
14	Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. <i>International Journal of Radiation Oncology Biology Physics</i> , 1987, 13, 403-426.	0.4	328
15	The effect of platinum derivatives on interfacial properties of DNA. <i>Biophysical Chemistry</i> , 1987, 28, 191-197.	1.5	8
16	Cisplatin Toxicity in Cats. <i>Journal of Veterinary Internal Medicine</i> , 1987, 1, 29-35.	0.6	57
17	Effects of cis-diamminedichloroplatinum (II) upon haemopoietic progenitors and the haemopoietic microenvironment in mice. <i>British Journal of Haematology</i> , 1988, 68, 3-9.	1.2	5
18	Cisplatin Therapy in 41 Dogs With Malignant Tumors. <i>Journal of Veterinary Internal Medicine</i> , 1988, 2, 41-46.	0.6	65

#	ARTICLE	IF	CITATIONS
19	Analysis by the Carrâ€“Purcellâ€“Meiboomâ€“Gill sequence of the influence of P388 leukemia and of cis-diamminedichloroplatinum(II) nephrotoxicity on water compartmentalization in kidneys and spleens of mice. <i>Magnetic Resonance in Medicine</i> , 1988, 7, 449-462.	1.9	10
20	The relationship between serum water proton T1 and protein content in the p388 leukemic mouse and the effect of chemotherapy by CIS-diamminedichloroplatinum(II). <i>NMR in Biomedicine</i> , 1988, 1, 80-89.	1.6	2
21	Biological activity of organometallic bismuth compounds. <i>Biology of Metals</i> , 1988, 1, 69-76.	1.1	36
22	Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations. <i>Investigational New Drugs</i> , 1988, 6, 259-64.	1.2	6
23	Resistance of cisplatin and analogues: mechanisms and potential clinical implications. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 22, 325-332.	1.1	92
25	The Mechanism of Acquired Resistance to Cisplatin by a Human Ovarian Cancer Cell Line. <i>Japanese Journal of Cancer Research</i> , 1988, 79, 632-635.	1.7	16
26	RADIATION AND CISPLATIN FOR TREATMENT OF CANINE URINARY BLADDER CARCINOMA. <i>Veterinary Radiology</i> , 1988, 29, 264-268.	0.2	19
27	Increased capacity of lymphocytes to lyse tumor cells in vitro and production of lymphotoxins after cisplatin treatment. <i>International Journal of Immunopharmacology</i> , 1988, 10, 753-761.	1.1	8
28	Transplacental passage of titanium after treatment with titanocene dichloride. <i>Toxicology</i> , 1988, 48, 253-260.	2.0	13
29	Electrochemical analysis of antitumor platinum drugs and their complexes with DNA. <i>Bioelectrochemistry</i> , 1988, 19, 145-160.	1.0	22
30	cis-dichloro(substituted o-phenylenediamine)-platinum(II) compounds. <i>Inorganica Chimica Acta</i> , 1988, 142, 185-186.	1.2	17
31	Antitumor and toxicologic properties of the organometallic anticancer agent vanadocene dichloride. <i>Inorganica Chimica Acta</i> , 1988, 152, 117-124.	1.2	50
32	Antitumor activity of some organometallic bismuth(III)thiolates. <i>Inorganica Chimica Acta</i> , 1988, 152, 49-52.	1.2	57
33	Electrochemical analysis of antitumor platinum drugs and their complexes with DNA. <i>Journal of Electroanalytical Chemistry and Interfacial Electrochemistry</i> , 1988, 253, 145-160.	0.3	0
34	Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. <i>Biochemical Pharmacology</i> , 1988, 37, 443-447.	2.0	37
35	Noncovalent complexes of water-soluble polymers and organoplatinum compounds as potential time-release antitumor agents. <i>Makromolekulare Chemie Macromolecular Symposia</i> , 1988, 19, 329-339.	0.6	14
36	The isolation and characterization of cisplatin-resistant rat ovarian cancer cells. <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 851-859.	0.9	5
37	Ultrastructural localization of cisplatin in Ehrlich ascites tumor cells. <i>Cancer Letters</i> , 1988, 39, 179-183.	3.2	0

#	ARTICLE	IF	CITATIONS
38	The Effect of Cisplatin and Fluorouracil on Xenografted Human Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology</i> , 1988, 114, 162-167.	1.5	15
39	Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 650-653.	3.3	97
40	A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.. <i>Journal of Clinical Oncology</i> , 1989, 7, 651-661.	0.8	175
41	Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. <i>Carcinogenesis</i> , 1989, 10, 1681-1684.	1.3	29
42	The Role of Drug Sequence in Therapeutic Selectivity of the Combination of 5-Fluorouracil and Cis-Platin. <i>Selective Cancer Therapeutics</i> , 1989, 5, 169-177.	0.5	12
43	Differential Gene Expression in Human Cancer Cells Resistant to Cisplatin. <i>Cancer Investigation</i> , 1989, 7, 581-587.	0.6	50
44	Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: Effect of the neuroprotecting peptide ORG.2766. <i>Toxicology and Applied Pharmacology</i> , 1989, 99, 334-343.	1.3	35
45	Improved use of buthionine sulfoximine to prevent cisplatin nephrotoxicity in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 1989, 115, 418-422.	1.2	8
46	Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin. <i>International Journal of Cancer</i> , 1989, 43, 1091-1097.	2.3	11
47	Cisplatin-induced Neurotoxicity with Seizures in Frogs. <i>Annals of Neurology</i> , 1989, 26, 336-341.	2.8	5
48	In vivo release of cisplatin from a needle-type copolymer formulation implanted in rat kidney. <i>Biomaterials</i> , 1989, 10, 16-22.	5.7	10
49	Organo-transition-metal chemistry of highly fluorinated ligand systems. <i>Journal of Organometallic Chemistry</i> , 1989, 372, 33-40.	0.8	9
51	Action of cisplatin and cycloplatam on the rat kidney. <i>Bulletin of Experimental Biology and Medicine</i> , 1989, 108, 965-966.	0.3	0
52	Ionic titanocene complexes: a new type of antitumor agent. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 23-7.	1.1	12
53	In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 129-34.	1.1	7
54	In vitro antagonism between cisplatin and vinca alkaloids. <i>British Journal of Cancer</i> , 1989, 59, 36-41.	2.9	9
55	5-HT ₃ receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. <i>British Journal of Pharmacology</i> , 1989, 97, 247-255.	2.7	210
56	Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1273-1279.	0.9	5

#	ARTICLE	IF	CITATIONS
57	Drug Selectivity and Membrane Transport Properties of Normal Human Lymphocytes. <i>Chemotherapy</i> , 1989, 35, 363-372.	0.8	4
58	Metal compounds in cancer chemotherapy. <i>Coordination Chemistry Reviews</i> , 1990, 99, 253-296.	9.5	212
59	Palladium and platinum. <i>Coordination Chemistry Reviews</i> , 1990, 101, vii.	9.5	23
60	Combined cisplatin and radiation therapy in patients with invasive bladder cancer. <i>International Urology and Nephrology</i> , 1990, 22, 337-344.	0.6	4
61	Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells. <i>Investigational New Drugs</i> , 1990, 8, 263-8.	1.2	4
62	Clinical trial and pharmacokinetics of carboplatin 560 mg/m ² in children. <i>Medical and Pediatric Oncology</i> , 1990, 18, 459-465.	1.0	15
63	Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. <i>Biophysical Chemistry</i> , 1990, 35, 129-141.	1.5	139
64	Activation of murine macrophages by tumor necrosis factor, interleukin-1, interferon- γ and cisplatin. <i>Immunology Letters</i> , 1990, 26, 45-50.	1.1	11
65	Reduction of Tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (Tetraplatin) Toxicity by the Administration of Diethyldithiocarbamate (DDTC), S-2(3-Aminopropylamino)ethylphosphorothioic Acid (WR-2721), or Sodium Selenite in the Fischer 344 Rat. <i>Toxicological Sciences</i> , 1990, 14, 706-719.	1.4	0
66	Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 383-390.	0.9	37
67	Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat*1, *2. <i>Fundamental and Applied Toxicology</i> , 1990, 14, 706-719.	1.9	7
68	Crossover study with cisplatin or carboplatin in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1990, 39, 146-149.	0.6	10
69	Induction of micronucleated and binucleate cells in Chinese hamster ovary (CHO) cells by cis-diamminedichloroplatinum (II): a morphological and morphometric study. <i>Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure</i> , 1990, 241, 115-124.	1.2	15
70	Phenotypic reversion of cisplatin resistance in human cells accompanies reduced host cell reactivation of damaged plasmid. <i>Biochemical and Biophysical Research Communications</i> , 1990, 170, 851-859.	1.0	11
71	Toxicity of cis-Diamminedichloroplatinum (II) (Cisplatin) in the frog, <i>rana pipiens</i> . <i>Journal of Comparative Pathology</i> , 1990, 103, 387-398.	0.1	2
72	Cisplatin induces the small heat shock protein HSP25 and thermotolerance in Ehrlich ascites tumor cells. <i>Biochemical and Biophysical Research Communications</i> , 1991, 180, 243-248.	1.0	49
73	Relative lack of toxicity of transplatin compared with cisplatin in rodents. <i>Journal of Comparative Pathology</i> , 1991, 105, 367-375.	0.1	18
74	Cisplatin resistance in human cancers. , 1991, 52, 385-406.		92

#	ARTICLE	IF	CITATIONS
75	Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. <i>Biochemical Pharmacology</i> , 1991, 42, 357-363.	2.0	44
76	The Therapeutic Impact of Dipyridamole: Chemopotential of the Cytotoxic Combination 5-Fluorouracil/Cisplatin in an Animal Model of Human Bladder Cancer. <i>Journal of Urology</i> , 1991, 146, 1418-1424.	0.2	9
77	Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. <i>British Journal of Cancer</i> , 1991, 63, 195-200.	2.9	27
78	Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA. <i>Molecular and Cellular Biology</i> , 1991, 11, 2075-2080.	1.1	62
79	Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II). <i>Biochemical Journal</i> , 1991, 277, 875-878.	1.7	58
80	Effect of TNF priming of murine peritoneal macrophages on their activation to a tumoricidal state. <i>Immunology Letters</i> , 1991, 28, 127-133.	1.1	8
81	Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin. <i>Immunology Letters</i> , 1991, 27, 199-204.	1.1	18
82	Potential negative regulation of damage-recognition proteins in cisplatin-resistant HeLa cells in response to DNA damage. <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1991, 264, 59-66.	1.2	7
83	Sequence-dependent Termination of Mammalian DNA Polymerase Reaction by a New Platinum Compound, (-)-(R)-2-Aminomethylpyrrolidine(1,1-cyclobutane-dicarboxylato)-2-platinum(II) Monohydrate. <i>Japanese Journal of Cancer Research</i> , 1991, 82, 433-439.	1.7	9
84	Multi-Drug Resistance Genes in the Management of Neoplastic Disease. <i>Journal of Veterinary Internal Medicine</i> , 1991, 5, 239-247.	0.6	14
85	Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). <i>International Journal of Cancer</i> , 1991, 47, 252-260.	2.3	85
86	Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. <i>International Journal of Cancer</i> , 1991, 48, 265-269.	2.3	45
87	Combining independently effective anticancer agents may not augment the independent antitumor effects: A study using human digestive organ cancer xenograft lines in nude mice. <i>Journal of Surgical Oncology</i> , 1991, 48, 252-259.	0.8	1
88	Antibodies against cisplatin-modified DNA and cisplatin-modified (di) nucleotides. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 185-191.	1.1	29
89	Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. <i>Journal of Neuro-Oncology</i> , 1991, 11, 27-35.	1.4	42
90	DNA-protein cross-linking in L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II). <i>Molecular Biology Reports</i> , 1991, 15, 81-86.	1.0	5
91	Uptake and Retention of Platinum in Patients Undergoing Cisplatin Therapy. <i>Acta Oncologica</i> , 1991, 30, 315-319.	0.8	15
92	Neoadjuvant intraarterial chemotherapy of soft tissue sarcomas. <i>Annals of Oncology</i> , 1992, 3, S127-S129.	0.6	7

#	ARTICLE	IF	CITATIONS
93	Percolation and Release of Cisplatin Loaded in Poly(lactide-co-glycolide) Microspheres for Chemoembolization. <i>Journal of Bioactive and Compatible Polymers</i> , 1992, 7, 149-160.	0.8	4
94	Cisplatin-Induced Emesis in <i>Suncus Murinus</i> . <i>The Japanese Journal of Pharmacology</i> , 1992, 58, 321-324.	1.2	38
95	Damage-recognition proteins as a potential indicator of DNA-damage-mediated sensitivity or resistance of human cells to ultraviolet radiation. <i>Biochemical Journal</i> , 1992, 282, 203-207.	1.7	20
96	Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. , 1992, 55, 1-30.		37
97	Interaction of D, L- and D-tetraplatin with hyperthermia in vitro and in vivo. <i>European Journal of Cancer</i> , 1992, 28, 794-800.	1.3	8
98	The influence of hyperthermia on the uptake of cisplatin in the rat cervical spinal cord. <i>European Journal of Cancer</i> , 1992, 28, 1139-1143.	1.3	5
99	The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin. <i>Gynecologic Oncology</i> , 1992, 47, 28-33.	0.6	10
100	The effects of cisplatin on murine metaphase II oocytes. <i>Gynecologic Oncology</i> , 1992, 47, 348-352.	0.6	23
101	Cisplatin-Induced Emesis in <i>Suncus Murinus</i> . <i>The Japanese Journal of Pharmacology</i> , 1992, 58, 321-324.	1.2	6
102	Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. <i>Acta Neuropathologica</i> , 1992, 84, 364-71.	3.9	138
103	Ionic rhencene derivatives with antitumor activity. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 29, 361-366.	1.1	21
104	Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers. <i>Immunology Letters</i> , 1992, 34, 183-188.	1.1	21
105	Characterization of a UV-damage recognition factor in vitro that is associated with UV resistance in HeLa cells. <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1992, 281, 105-113.	1.2	2
106	Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 643-647.	0.1	18
107	Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. <i>International Journal of Cancer</i> , 1992, 52, 813-817.	2.3	43
108	Cisplatin-Induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. <i>Cancer</i> , 1992, 69, 203-207.	2.0	116
109	Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. <i>International Journal of Cancer</i> , 1993, 53, 662-666.	2.3	12
110	Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. <i>Cancer</i> , 1993, 71, 1571-1580.	2.0	98

#	ARTICLE	IF	CITATIONS
111	Effect of In vivo administration of cisplatin on the colony forming ability of murine bone marrow cells. <i>International Journal of Immunopharmacology</i> , 1993, 15, 281-286.	1.1	7
112	New platinum antitumor complexes. <i>Critical Reviews in Oncology/Hematology</i> , 1993, 15, 191-219.	2.0	199
113	Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues. <i>Journal of the American Society for Mass Spectrometry</i> , 1993, 4, 588-595.	1.2	31
114	Correlation of the in vitro cytotoxicity of ethyldeshydroxysparosomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 31, 289-294.	1.1	1
115	Possible relationship between micronucleated and binucleated cells induced by cisplatin in cultured CHO cells. <i>Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology</i> , 1993, 291, 35-41.	0.4	13
116	The thermal degradation characteristics of selected organoplatinum antitumor agents. <i>Journal of Thermal Analysis</i> , 1993, 40, 395-403.	0.7	8
117	Radiomimetic Effect of Cisplatin on Cucumber Root Development: the Relationship between Cell Division and Cell Growth. <i>Annals of Botany</i> , 1993, 72, 143-149.	1.4	2
118	Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 157-162.	1.1	10
119	Effects of the anticancer drug cis-diamminedichloroplatinum(II) on the activities of calf thymus DNA polymerase .epsilon.. <i>Biochemistry</i> , 1993, 32, 841-848.	1.2	34
121	The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 42, 94-94.	1.0	0
122	Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. <i>Carcinogenesis</i> , 1993, 14, 559-561.	1.3	108
123	Effects of cis-Platin on t-RNA of <i>Saccharomyces cerevisiae</i> . <i>Bioscience, Biotechnology and Biochemistry</i> , 1993, 57, 1198-1199.	0.6	2
125	Tissue Distribution of <i>cis</i>-Diamminedichloroplatinum (II) following Intraperitoneal Administration to Patients with Recurrent Gastric Cancer. <i>Oncology</i> , 1993, 50, 214-217.	0.9	5
126	CURE WITH CISPLATIN (II) OF MURINE MALARIA INFECTION AND IN VITRO INHIBITION OF A CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM ISOLATE. <i>Japanese Journal of Medical Science and Biology</i> , 1994, 47, 241-252.	0.4	16
127	REVIEW: INTERACTIONS OF METAL IONS WITH NUCLEIC ACIDS AND THEIR SUBUNITS. AN ELECTROCHEMICAL APPROACH. <i>Journal of Coordination Chemistry</i> , 1994, 33, 191-217.	0.8	27
128	SYNERGISM OF CYTOTOXICITY BETWEEN CIS-DIAMINEDICHLORO-PLATINUM-(II) AND CIS-DIAMINE(1,1-CYCLOBUTANEDICARBOXYLATE)-PLATINUM-(II). <i>International Journal of Oncology</i> , 1994, 4, 329.	1.4	0
129	MECHANISM-RELATED CIRCUMVENTION OF CISPLATIN RESISTANCE IN HUMAN OVARIAN-CARCINOMA CELLS BY (-)-(R)-2-AMINOMETHYLPYRROLIDINE(1,1-CYCLOBUTANEDIACARBOXYLATO)-PLATINUM (II) MONOHYDRATE AND MODULATION OF ITS SENSITIVITY BY 12-O-TETRADECANOYLPHORBOL-13-ACETATE. <i>International Journal of Oncology</i> , 1994, 5, 1309-14.	1.4	0
130	Role of calcium and calmodulin in the activation of murine peritoneal macrophages with cisplatin. <i>International Journal of Immunopharmacology</i> , 1994, 16, 1003-1010.	1.1	13

#	ARTICLE	IF	CITATIONS
131	Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells. <i>European Journal of Pharmacology</i> , 1994, 268, 347-355.	2.7	15
132	Formation and characterization of cisplatin-loaded poly(benzyl L-glutamate) microspheres for chemoembolization. <i>Pharmaceutical Research</i> , 1994, 11, 1792-1799.	1.7	14
133	Reduced inhibition of DNA synthesis and G2 arrest during the cell cycle of resistant HeLa cells in response to cis-diamminedichloroplatinum. <i>Journal of Biomedical Science</i> , 1994, 1, 131-138.	2.6	16
134	Platinum anticancer drugs. , 1994, , 32-45.		4
135	Modern chemotherapy for gynaecological cancer. Part 1: models, mechanisms and methods. <i>Current Obstetrics & Gynaecology</i> , 1994, 4, 14-22.	0.2	0
136	Use of a monoclonal antibody to detect DNA damage caused by the anticancer drug cis-diamminedichloroplatinum (II) in vivo and in vitro. <i>FEBS Letters</i> , 1994, 354, 103-109.	1.3	9
137	What is the place of carboplatin in paediatric oncology?. <i>European Journal of Cancer</i> , 1994, 30, 194-201.	1.3	39
138	New Platinum Agents. <i>Drugs and Aging</i> , 1994, 5, 85-95.	1.3	16
139	Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. <i>British Journal of Cancer</i> , 1994, 70, 415-420.	2.9	18
140	Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 1995, 13, 26-32.	0.8	171
141	Cisplatin and DNA repair in cancer chemotherapy. <i>Trends in Biochemical Sciences</i> , 1995, 20, 435-439.	3.7	458
142	Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. <i>International Journal of Cancer</i> , 1995, 60, 611-615.	2.3	20
143	Preclinical antitumor activity of ethyldeshydroxysparosomycin in combination with cisplatin. <i>Investigational New Drugs</i> , 1995, 13, 23-32.	1.2	5
144	A phase I trial of 5-day continuous infusion cisplatin and interferon ?. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 37, 39-46.	1.1	3
145	Stimulation of radial expansion in arabidopsis roots by inhibitors of actomyosin and vesicle secretion but not by various inhibitors of metabolism. <i>Planta</i> , 1995, 197, 514-21.	1.6	79
146	Effect of cisplatin administration on the proliferation and differentiation of bone marrow cells of tumour-bearing mice. <i>Immunology and Cell Biology</i> , 1995, 73, 220-225.	1.0	13
147	Effect of cisplatin and FK565 on the activation of tumor-associated and bone marrow-derived macrophages by Dalton's lymphoma. <i>International Journal of Immunopharmacology</i> , 1995, 17, 1-7.	1.1	21
148	Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1995, 13, 1493-1498.	1.4	37

#	ARTICLE	IF	CITATIONS
149	Nuclear microanalysis of platinum and trace elements in cisplatin-resistant human ovarian adenocarcinoma cells. <i>Nuclear Instruments & Methods in Physics Research B</i> , 1995, 104, 292-298.	0.6	19
150	Lysosomal Changes in Rat Spinal Ganglia Neurons after Prolonged Treatment with Cisplatin. <i>Cells Tissues Organs</i> , 1995, 153, 236-242.	1.3	6
151	Cycloplatom: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. <i>European Journal of Cancer</i> , 1995, 31, 356-361.	1.3	27
152	The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1267, 25-30.	1.9	9
153	Effect of Dalton's lymphoma on the antigen presentation of murine peritoneal macrophages. <i>Cancer Letters</i> , 1995, 92, 151-157.	3.2	13
154	Physiological and Toxicological Changes in the Skin Resulting from the Action and Interaction of Metal Ions. <i>Critical Reviews in Toxicology</i> , 1995, 25, 397-462.	1.9	121
155	Cytotoxicity of antitumor platinum complexes with l-buthionine-(R, S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 431-438.	1.1	4
156	Chromosome damage induced by carboplatin (CBDCA). <i>Toxicology Letters</i> , 1995, 76, 97-103.	0.4	16
157	Repair of Cisplatin-DNA Adducts by the Mammalian Excision Nuclease. <i>Biochemistry</i> , 1996, 35, 10004-10013.	1.2	316
158	Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. <i>European Journal of Cancer</i> , 1996, 32, 1766-1773.	1.3	11
159	In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin. <i>European Journal of Cancer</i> , 1996, 32, 2011-2018.	1.3	8
160	Inhibition by arsenite of anticancer drug cis-diamminedichloroplatinum(II) induced DNA repair and drug resistance in HeLa cells. <i>Environmental Toxicology and Pharmacology</i> , 1996, 1, 199-205.	2.0	4
161	Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair. <i>European Journal of Pharmacology</i> , 1996, 305, 213-222.	1.7	9
162	Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel. <i>Biochemical Pharmacology</i> , 1996, 52, 1855-1865.	2.0	536
163	Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. <i>European Journal of Surgical Oncology</i> , 1996, 22, 528-531.	0.5	26
164	Glutathione and Drug Resistance. <i>Cancer Investigation</i> , 1996, 14, 158-168.	0.6	68
165	Effect of cisplatin and c-myc antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. <i>British Journal of Cancer</i> , 1996, 74, 387-393.	2.9	22
166	DNA adducts from chemotherapeutic agents. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1996, 355, 13-40.	0.4	240

#	ARTICLE	IF	CITATIONS
167	Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines with special reference to cisplatin. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 665-670.	1.2	31
168	Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 421-426.	1.2	3
169	A high performance liquid chromatography ? inductively coupled plasma-mass spectrometry interface employing desolvation for speciation studies of platinum in chemotherapy drugs. <i>Analytical and Bioanalytical Chemistry</i> , 1996, 355, 202-208.	1.9	42
170	Biotransformation of the platinum drug JM216 following oral administration to cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 155-162.	1.1	114
171	Quantitative X-ray imaging of labelled molecules in tissues and cells. <i>Journal of Microscopy</i> , 1996, 183, 181-186.	0.8	5
172	Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. , 1996, 77, 1797-1808.		36
173	Study of interactions between titanocene dichloride and mononucleotides by high-resolution 1H- and 31P-nuclear magnetic resonance. <i>Transition Metal Chemistry</i> , 1996, 21, 322-326.	0.7	7
174	Host cell reactivation of cisplatin-treated adenovirus is reduced in nucleotide excision repair deficient mammalian cells and several human tumour cells. <i>International Journal of Oncology</i> , 1996, 9, 1121-7.	1.4	1
175	Evaluation of Intratumoral Injection of Poly(D,L-lactide) Cisplatin Microspheres in Rats with Breast Tumors Using [131I]iodomisonidazole (IMISO). <i>Drug Delivery</i> , 1997, 4, 107-113.	2.5	2
176	Oral platinum analogue JM216, a radiosensitizer in oxic murine cells. <i>International Journal of Radiation Biology</i> , 1997, 72, 675-683.	1.0	14
177	Risk factors for the development of severe cisplatin neurotoxicity. <i>International Journal of Oncology</i> , 1997, 11, 365-70.	1.4	1
178	Magnitude and Pattern of Inner and Outer Hair Cell Loss in Chinchilla as a Function of Carboplatin Dose. <i>International Journal of Audiology</i> , 1997, 36, 301-311.	0.9	36
179	Cisplatin Inhibits Protein Synthesis in Rabbit Reticulocyte Lysate by Causing an Arrest in Elongation. <i>Archives of Biochemistry and Biophysics</i> , 1997, 344, 200-207.	1.4	35
180	Activation of P388D1 macrophage cell line by chemotherapeutic drugs. <i>Life Sciences</i> , 1997, 60, 1239-1248.	2.0	11
181	Preferential formation and decreased removal of cisplatinâ€™DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 1997, 391, 79-86.	0.9	72
182	Identification of semaphorin E as a non-MDR drug resistance gene of human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 14713-14718.	3.3	85
183	The effect of a single therapeutic dose of cisplatin on GFR in dogs. <i>Oncology Reports</i> , 1997, 4, 153.	1.2	2
184	Variations in Tumor Levels of Cis-Platinum through a Course of Fractionated Radiotherapy in Patients with Non-Small Cell Lung Cancer. <i>Tumori</i> , 1997, 83, 904-906.	0.6	0

#	ARTICLE	IF	CITATIONS
185	Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. <i>British Journal of Cancer</i> , 1997, 76, 77-82.	2.9	21
186	In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 493-497.	1.1	51
187	Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 94-97.	1.1	15
188	Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. <i>Journal of Neuro-Oncology</i> , 1998, 36, 31-40.	1.4	50
189	Mutant p53 protein expression interferes with p53-independent apoptotic pathways. <i>Oncogene</i> , 1998, 16, 3269-3277.	2.6	135
190	Vitamin C mediated protection on cisplatin induced mutagenicity in mice. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1998, 421, 139-148.	0.4	62
191	Serotonin 5-HT 3 receptor antagonists prevent cisplatin-induced emesis in <i>Cryptotis parva</i> : a new experimental model of emesis. <i>Journal of Neural Transmission</i> , 1998, 105, 1143-1154.	1.4	59
193	LFA-1-dependent tumoricidal activity of cisplatin-treated macrophages. <i>Immunology and Cell Biology</i> , 1998, 76, 343-349.	1.0	8
194	Antigen presentation by cisplatin-activated macrophages: Role of soluble factor(s) and second messengers. <i>Immunology and Cell Biology</i> , 1998, 76, 513-519.	1.0	21
195	Cisplatin-induced activation of murine bone marrow-derived macrophages require protein tyrosine phosphorylation. <i>International Journal of Immunopharmacology</i> , 1998, 19, 683-690.	1.1	7
196	Protein kinase C: a potential pathway of macrophage activation with cisplatin. <i>Immunology Letters</i> , 1998, 61, 179-186.	1.1	11
197	Cisplatin-treated macrophages produce oncostatin M: regulation by serine/threonine and protein tyrosine kinases/phosphatases and Ca ²⁺ /calmodulin. <i>Immunology Letters</i> , 1998, 62, 159-164.	1.1	21
198	Mechanism of NF- κ B translocation in macrophages treated in vitro with cisplatin. <i>Immunology Letters</i> , 1998, 63, 9-17.	1.1	13
199	Expression and activation of lyn in macrophages treated in vitro with cisplatin: regulation by kinases, phosphatases and Ca ²⁺ /calmodulin. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1998, 1405, 171-179.	1.9	15
200	Binding of terbium and cisplatin to C13* human ovarian cancer cells using time-resolved terbium luminescence. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1998, 1448, 85-98.	1.9	9
201	Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. <i>European Journal of Cancer</i> , 1998, 34, 1522-1534.	1.3	685
202	Involvement of ras and map kinase (ERK α) in cisplatin-induced activation of murine bone marrow-derived macrophages. <i>IUBMB Life</i> , 1998, 45, 527-534.	1.5	5
203	Glutathione-related mechanisms in cellular resistance to anticancer drugs.. <i>International Journal of Oncology</i> , 1998, 12, 871-82.	1.4	60

#	ARTICLE	IF	CITATIONS
204	Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo.. International Journal of Oncology, 1998, 13, 421-8.	1.4	9
205	Establishment and Characterization of Cisplatin-Resistant Human Epidermoid Carcinoma Cell Line, A431 Cell. Chemotherapy, 1998, 44, 414-420.	0.8	15
206	Studies on the Chromosomes of Murine Dalton's Lymphoma Cells and the Effect of Cisplatin on Chromosomes of These Cells and Bone Marrow Cells in vivo.. Cytologia, 1998, 63, 405-413.	0.2	5
207	Expression and activation of RAS and mitogen-activated protein kinases in macrophages treated in vitro with cisplatin: Regulation by kinases, phosphatases and Ca ²⁺ /calmodulin. Immunology and Cell Biology, 1999, 77, 356-363.	1.0	8
208	Multinuclear NMR study and crystal structures of complexes of the types cis- and trans-Pt(Ypy)2X2, where Ypy=pyridine derivative and X=Cl and I. Inorganica Chimica Acta, 1999, 295, 25-38.	1.2	106
209	Coordination compounds in medicinal chemistry. Coordination Chemistry Reviews, 1999, 184, 67-89.	9.5	82
210	Cytotoxicity, Apoptosis, and in Vitro DNA Damage Induced by Potassium Chromate. Toxicology and Applied Pharmacology, 1999, 161, 75-81.	1.3	49
211	Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1445, 123-133.	2.4	11
212	Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells. Biochemical Pharmacology, 1999, 58, 69-76.	2.0	30
213	Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. Chemico-Biological Interactions, 1999, 117, 99-115.	1.7	23
214	Comprehensive ab initio quantum mechanical and molecular orbital (MO) analysis of cisplatin: Structure, bonding, charge density, and vibrational frequencies. Journal of Computational Chemistry, 1999, 20, 365-382.	1.5	88
215	Toxicology and antitumour activity of ferrocenylamines and platinum derivatives. Applied Organometallic Chemistry, 1999, 13, 163-174.	1.7	27
216	Effect of Cisplatin on the Lactate Dehydrogenase Activity and its Isozyme Pattern in Dalton's Lymphoma Bearing Mice.. Cytologia, 1999, 64, 259-267.	0.2	7
217	Potential Transmission of the Cytogenetic Effects of Cisplatin in the Male Germline Cells of Swiss Mice. Journal of Chemotherapy, 2000, 12, 352-359.	0.7	16
218	Cisplatin-based therapy: a neurological and neuropsychological review. , 2000, 9, 29-39.		91
219	Effects of selenium pretreatment on cisplatin-induced chromosome aberrations in Wistar rats. Teratogenesis, Carcinogenesis, and Mutagenesis, 2000, 20, 341-348.	0.8	14
220	cis-Bis(3,6-dihydro-2H-1,2-oxazine-N)diiodoplatinum(II) and cis-bis(3,4,5,6-tetrahydro-2H-1,2-oxazine-N)diiodoplatinum(II). Acta Crystallographica Section C: Crystal Structure Communications, 2000, 56, e335-e337.	0.4	2
221	cis- and trans-Dichloro(3,6-dihydro-1,2-oxazine-N)(dimethyl sulfoxide-S)-platinum(II). Acta Crystallographica Section C: Crystal Structure Communications, 2000, 56, 64-66.	0.4	4

#	ARTICLE	IF	CITATIONS
222	Platinum pharmacokinetics in sulphur-crested cockatoos (<i>Cacatua galerita</i>) following single-dose cisplatin infusion. <i>Australian Veterinary Journal</i> , 2000, 78, 406-411.	0.5	21
223	Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. <i>Cell Biology and Toxicology</i> , 2000, 16, 363-373.	2.4	31
224	X-ray Structure of Cytotoxic trans-[PtCl ₂ (dimethylamine)(isopropylamine)]·2H ₂ O: Interstrand Cross-Link Efficiency, DNA Sequence Specificity, and Inhibition of the B _A →Z Transition. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2411-2418.	2.9	50
225	Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. <i>Archives of Toxicology</i> , 2000, 74, 300-307.	1.9	12
226	X-ray microimaging of cisplatin distribution in ovarian cancer cells. <i>AIP Conference Proceedings</i> , 2000, , .	0.3	0
227	Cytogenetic Toxicity of Cisplatin in Bone Marrow Cells of Swiss Mice. <i>Journal of Chemotherapy</i> , 2000, 12, 173-182.	0.7	29
228	Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity. <i>European Journal of Surgical Oncology</i> , 2000, 26, 213-221.	0.5	14
229	Effects of the antioxidants curcumin and vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2000, 465, 131-137.	0.9	94
230	Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2000, 86, 84-93.	1.4	85
231	Interaction of cisplatin with planar model membranes: dose dependent change in electrical characteristics. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2000, 1463, 230-240.	1.4	26
232	PROTECTIVE EFFECTS OF VITAMIN C AGAINST CISPLATIN-INDUCED NEPHROTOXICITY AND LIPID PEROXIDATION IN ADULT RATS: A DOSE-DEPENDENT STUDY. <i>Pharmacological Research</i> , 2000, 41, 405-411.	3.1	206
233	Preclinical Perspectives on Platinum Resistance. <i>Drugs</i> , 2000, 59, 1-8.	4.9	225
234	Alterations in Cell Cycle Regulation Underlie Cisplatin Induced Apoptosis of Dorsal Root Ganglion Neurons in Vivo. <i>Neurobiology of Disease</i> , 2001, 8, 1027-1035.	2.1	59
235	Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. <i>Pharmacological Research</i> , 2001, 43, 145-150.	3.1	159
236	Antioxidant action of bixin against cisplatin-induced chromosome aberrations and lipid peroxidation in rats. <i>Pharmacological Research</i> , 2001, 43, 561-566.	3.1	99
237	Cellular Uptake, DNA Binding and Apoptosis Induction of Cytotoxic Trans-[PtCl ₂ (N,N-dimethylamine)(isopropylamine)] in A2780cisR Ovarian Tumor Cells. <i>Metal-Based Drugs</i> , 2001, 8, 29-37.	3.8	15
238	Characterization of cis-Diamminedichloroplatinum (II)-Resistant Murine Cell Lines Derived from Metallothionein Null Cells. <i>Journal of Health Science</i> , 2001, 47, 378-384.	0.9	4
239	CISPLATIN INDUCES MODIFICATIONS IN THE DEVELOPMENT OF CELL SURFACE PATTERNS OF CILIATES. <i>Cell Biology International</i> , 2001, 25, 1131-1138.	1.4	2

#	ARTICLE	IF	CITATIONS
240	Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin. <i>Journal of Neuro-Oncology</i> , 2001, 52, 23-36.	1.4	11
241	Hematotoxicity and blood glutathione levels after cisplatin treatment of tumor-bearing mice. <i>Cell Biology and Toxicology</i> , 2001, 17, 357-370.	2.4	25
242	Title is missing!. <i>Pharmaceutical Chemistry Journal</i> , 2001, 35, 442-449.	0.3	0
243	Oral Administration of Sodium Selenite Minimizes Cisplatin Toxicity on Proximal Tubules of Rats. <i>Biological Trace Element Research</i> , 2001, 83, 251-262.	1.9	16
245	Vitamin E Protection from/ Potentiation of the Cytogenetic Toxicity of Cisplatin in Swiss Mice. <i>Journal of Chemotherapy</i> , 2002, 14, 397-405.	0.7	14
246	Down-regulation of telomerase activity by anticancer drugs in human ovarian cancer cells. <i>Anti-Cancer Drugs</i> , 2002, 13, 595-598.	0.7	11
247	Binding to Cisplatin-Modified DNA by the <i>Saccharomyces cerevisiae</i> HMGB Protein Nhp6A. <i>Biochemistry</i> , 2002, 41, 5404-5414.	1.2	38
248	The effects of oral glutamine on cisplatin-induced genotoxicity in Wistar rat bone marrow cells. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2002, 518, 65-70.	0.9	21
249	Sialic acid changes in Dalton's lymphoma-bearing mice after cyclophosphamide and cisplatin treatment. <i>Brazilian Journal of Medical and Biological Research</i> , 2002, 35, 549-553.	0.7	21
250	The interaction of cisplatin and analogues with DNA in reconstituted chromatin. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2002, 1579, 142-152.	2.4	48
251	PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. <i>Journal of Controlled Release</i> , 2002, 79, 123-135.	4.8	452
252	Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. <i>International Journal of Cancer</i> , 2002, 100, 238-243.	2.3	22
253	Synthesis, Characterization and Antitumor Studies of Mn(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) Complexes of N-Salicyloyl-N'-o-hydroxythiobenzhydrazide. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 887-895.	1.4	19
254	Studies of the binding of a series of platinum(IV) complexes to plasma proteins. <i>Journal of Inorganic Biochemistry</i> , 2002, 88, 260-267.	1.5	58
255	Testis-specific HMG-domain protein alters the responses of cells to cisplatin. <i>Journal of Inorganic Biochemistry</i> , 2002, 91, 451-462.	1.5	79
256	Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C. <i>International Journal of Pharmaceutics</i> , 2002, 240, 23-31.	2.6	31
257	Synthesis, characterization and antitumor studies of transition metal complexes of o-hydroxydithiobenzoate. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 2693-2704.	1.4	14
258	Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. <i>Cell Biology and Toxicology</i> , 2002, 18, 349-358.	2.4	25

#	ARTICLE	IF	CITATIONS
259	Synthesis, characterization and antitumor studies of Mn(II), Ni(II), Cu(II) and Zn(II) complexes of N-nicotinoyl-n'-o-hydroxythiobenzhydrazide. <i>BioMetals</i> , 2003, 16, 311-320.	1.8	18
260	Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 459-464.	1.1	14
261	New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 3-15.	1.1	36
262	Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2003, 1653, 47-59.	3.3	36
263	Cisplatin-induced genotoxic effects and endogenous glutathione levels in mice bearing ascites Dalton's lymphoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 526, 9-18.	0.4	23
264	Capillary electrophoresis in anti-cancer metallodrug research: Advances and future challenges. <i>Electrophoresis</i> , 2003, 24, 2023-2037.	1.3	55
265	Structure and function of metalloantibiotics?. <i>Medicinal Research Reviews</i> , 2003, 23, 697-762.	5.0	195
266	Preparation, characterization and cytotoxic activity of new compounds trans-[PtCl ₂ NH ₃ (3-(hydroxymethyl)-pyridine)] and trans-[PtCl ₂ NH ₃ (4-(hydroxymethyl)-pyridine)]. <i>Polyhedron</i> , 2003, 22, 3379-3381.	1.0	28
267	Interferon- β downregulates Hsp27 expression and suppresses the negative regulation of cell death in oral squamous cell carcinoma lines. <i>Cell Death and Differentiation</i> , 2003, 10, 313-322.	5.0	20
268	Nucleotide Excision Repair from Site-Specifically Platinum-Modified Nucleosomes. <i>Biochemistry</i> , 2003, 42, 6747-6753.	1.2	98
269	β -Glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney. <i>European Journal of Cancer</i> , 2003, 39, 996-1003.	1.3	61
270	Treatment Options for Chemotherapy-Induced Nausea and Vomiting. <i>American Journal of Cancer</i> , 2003, 2, 15-26.	0.4	13
271	Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. <i>British Journal of Cancer</i> , 2003, 88, 951-956.	2.9	153
272	Changes in endogenous tissue glutathione level in relation to murine ascites tumor growth and the anticancer activity of cisplatin. <i>Brazilian Journal of Medical and Biological Research</i> , 2003, 36, 53-63.	0.7	33
273	Antioxidantes da dieta como inibidores da nefrotoxicidade induzida pelo antitumoral cisplatina. <i>Revista De Nutricao</i> , 2004, 17, 89-96.	0.4	15
274	Effects of BSO and L-Cysteine on Drug-Induced Cytotoxicity in Primary Cell Cultures: Drug, Cell Type, and Species-Specific Difference. <i>Drug and Chemical Toxicology</i> , 2004, 27, 269-280.	1.2	11
275	Cisplatin-induced Post-translational Modification of Histones H3 and H4. <i>Journal of Biological Chemistry</i> , 2004, 279, 20622-20625.	1.6	50
276	Molecular Determinants of the Cytotoxicity of Platinum Compounds. <i>Cancer Research</i> , 2004, 64, 356-362.	0.4	87

#	ARTICLE	IF	CITATIONS
277	Immunohistochemical localizations of secretin, cholecystokinin, and somatostatin in the rat small intestine after acute cisplatin treatment. <i>Experimental and Molecular Pathology</i> , 2004, 77, 238-245.	0.9	11
278	Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. <i>Chemico-Biological Interactions</i> , 2004, 147, 309-318.	1.7	70
279	Multinuclear NMR study and crystal structures of complexes of the types cis- and trans-Pt(amine) ₂ I ₂ . <i>Inorganica Chimica Acta</i> , 2004, 357, 2218-2230.	1.2	41
280	The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. <i>Pharmacological Research</i> , 2004, 50, 287-290.	3.1	82
281	Effects of the olive, extra virgin olive and canola oils on cisplatin-induced clastogenesis in Wistar rats. <i>Food and Chemical Toxicology</i> , 2004, 42, 1291-1297.	1.8	33
282	Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. <i>Oncology Reports</i> , 2005, 14, 1281.	1.2	8
283	Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. <i>Oncology Reports</i> , 2005, 13, 709.	1.2	7
284	Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret. <i>European Journal of Pharmacology</i> , 2005, 506, 241-247.	1.7	14
285	Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 189-198.	1.1	11
286	The frequencies of micronuclei induced by cisplatin in newborn rat astrocytes are increased by 50-Hz, 7.5- and 10-mT electromagnetic fields. <i>Environmental Health and Preventive Medicine</i> , 2005, 10, 138-143.	1.4	9
287	OTOTOXICIDADE, OTOPROTEÇÃO E AUTODEFESA DAS CÉLULAS CILIADAS DA CÂVEA. <i>Medicina</i> , 2005, 38, 279-289.	0.0	5
288	Cisplatin-Induced Cytotoxicity in BSO-Exposed Renal Proximal Tubular Epithelial Cells: Sex, Age, and Species. <i>Renal Failure</i> , 2005, 27, 629-633.	0.8	13
289	Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1585-1594.	1.9	37
290	Protective Effects of Increasing Vitamin E and A Doses on Cisplatin-Induced Oxidative Damage to Kidney Tissue in Rats. <i>Urologia Internationalis</i> , 2005, 75, 340-344.	0.6	41
291	Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1630-1647.	2.5	266
292	Evaluation of the clastogenicity and anticlastogenicity of the carotenoid bixin in human lymphocyte cultures. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2005, 585, 113-119.	0.9	41
293	Correlation of increased activities of Na ⁺ , K ⁺ -ATPase and Ca ²⁺ -ATPase with the reversal of cisplatin ototoxicity induced by d-methionine in guinea pigs. <i>Hearing Research</i> , 2005, 205, 102-109.	0.9	54
294	Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice. <i>Food and Chemical Toxicology</i> , 2005, 43, 117-122.	1.8	47

#	ARTICLE	IF	CITATIONS
295	Management Strategies for Partially Platinum-Sensitive Ovarian Cancer. <i>American Journal of Cancer</i> , 2006, 5, 341-354.	0.4	5
296	Chemoprotective Effect of <i>Phyllanthus maderaspatensis</i> . in Modulating Cisplatin-Induced Nephrotoxicity and Genotoxicity. <i>Pharmaceutical Biology</i> , 2006, 44, 100-106.	1.3	20
297	Organometallic Hydroxides of Transition Elements. <i>Chemical Reviews</i> , 2006, 106, 3813-3843.	23.0	90
298	Copper(II) and Manganese(III) complexes of N^2 -(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer. <i>Biochimie</i> , 2006, 88, 1209-1216.	1.3	38
299	Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. <i>DNA Repair</i> , 2006, 5, 219-225.	1.3	68
300	Muramyl peptides augment cytotoxic effect of tumor necrosis factor-alpha in combination with cytotoxic drugs on tumor cells. <i>International Immunopharmacology</i> , 2006, 6, 1377-1386.	1.7	7
301	Cisplatin. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 60-61.	0.3	5
302	Protective Effect of the Ethanol Extract of the Roots of <i>Brassica rapa</i> on Cisplatin-Induced Nephrotoxicity in LLC-PK1 Cells and Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 2436-2441.	0.6	74
303	Enhanced Susceptibility of Mouse Squamous Cell Carcinoma to Photodynamic Therapy Combined With Low-Dose Administration of Cisplatin. <i>Journal of Oral and Maxillofacial Surgery</i> , 2006, 64, 390-396.	0.5	17
304	Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat. <i>Cell Biochemistry and Function</i> , 2006, 24, 357-361.	1.4	111
305	Gamma camera scintigraphy of tumours using ^{195m}Pt -cisplatin. <i>Physics in Medicine and Biology</i> , 2006, 51, 1325-1332.	1.6	4
306	Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity. <i>Oncology Reports</i> , 2007, 17, 1213.	1.2	4
307	Vitamin C attenuates cisplatin-induced alterations in renal brush border membrane enzymes and phosphate transport. <i>Human and Experimental Toxicology</i> , 2007, 26, 419-426.	1.1	27
308	ARSENIC ACCUMULATION DECREASED IN METALLOTHIONEIN NULL CISPLATIN-RESISTANT CELL LINES. <i>Journal of Toxicological Sciences</i> , 2007, 32, 321-328.	0.7	3
309	Effects of the Licorice Extract against Tumor Growth and Cisplatin-Induced Toxicity in a Mouse Xenograft Model of Colon Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 2191-2195.	0.6	74
310	Interaction between cisplatin treated murine peritoneal macrophages and L929 cells: Involvement of adhesion molecules, cytoskeletons, upregulation of Ca^{2+} and nitric oxide dependent cytotoxicity. <i>Molecular Immunology</i> , 2007, 44, 2265-2276.	1.0	9
311	Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. <i>Oral Oncology</i> , 2007, 43, 477-483.	0.8	16
312	Riboflavin-mediated cellular photoinhibition of cisplatin-induced oxidative DNA breakage in mice epidermal keratinocytes. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2008, 24, 301-307.	0.7	18

#	ARTICLE	IF	CITATIONS
313	Licochalcone A Inhibits the Growth of Colon Carcinoma and Attenuates Cisplatin-Induced Toxicity without a Loss of Chemotherapeutic Efficacy in Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 48-54.	1.2	64
314	Effect of interferon-gamma priming on the activation of murine peritoneal macrophages to tumoricidal state by cisplatin, IL-1, and tumour necrosis factor (TNF): production of IL-1 and TNF. <i>Clinical and Experimental Immunology</i> , 2008, 88, 350-355.	1.1	17
315	<emphasistype="italic">In Vitro</emphasistype> Analysis of Cisplatin Functionalized Magnetic Nanoparticles in Combined Cancer Chemotherapy and Electromagnetic Hyperthermia. <i>IEEE Transactions on Nanobioscience</i> , 2008, 7, 15-19.	2.2	84
316	Isoliquiritigenin Inhibits Tumor Growth and Protects the Kidney and Liver Against Chemotherapy-Induced Toxicity in a Mouse Xenograft Model of Colon Carcinoma. <i>Journal of Pharmacological Sciences</i> , 2008, 106, 444-451.	1.1	74
317	The Anti-tumour Agent, Cisplatin, and its Clinically Ineffective Isomer, Transplatin, Produce Unique Gene Expression Profiles in Human Cells. <i>Cancer Informatics</i> , 2008, 6, CIN.S802.	0.9	13
318	The antiemetic interaction of δ^9 -tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 91, 367-373.	1.3	14
319	Modification of responses of <i>Candida albicans</i> to cisplatin by membrane damaging antimycotic agents. <i>Mycoses</i> , 1991, 34, 177-182.	1.8	9
320	Extract of <i>Prunus persica</i> flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice. <i>Phytotherapy Research</i> , 2009, 23, 999-1005.	2.8	16
321	Adenoviral-mediated pHyde Gene Transfer and Cisplatin Additively Inhibit Human Prostate Cancer Growth by Enhancing Apoptosis. <i>Prostate</i> , 2009, 69, 234-248.	1.2	4
322	Effect of Epidermal Growth Factor Receptor Inhibitor Alone and in Combination with Cisplatin on Growth of Vulvar Cancer Cells. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 642-648.	1.8	6
323	Polymer-metal complex micelles for the combination of sustained drug releasing and photodynamic therapy. <i>Journal of Materials Chemistry</i> , 2009, 19, 4627.	6.7	45
324	Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. <i>Journal of Translational Medicine</i> , 2009, 7, 77.	1.8	70
325	The unique gene expression profile of the anti-tumour agent, cisplatin, compared with its clinically ineffective isomer, transplatin. , 2009, , .		0
326	The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamate complexes. <i>Dalton Transactions</i> , 2009, , 10670.	1.6	86
328	Lutein improves antioxidant defense in vivo and protects against DNA damage and chromosome instability induced by cisplatin. <i>Archives of Toxicology</i> , 2010, 84, 811-822.	1.9	46
329	Conformational landscape of platinum(II)-tetraamine complexes: DFT and NBO studies. <i>Journal of Computer-Aided Molecular Design</i> , 2010, 24, 225-235.	1.3	10
330	Thermal degradation of platinum(IV) precursors to antitumor drugs. <i>Journal of Thermal Analysis and Calorimetry</i> , 2010, 102, 499-503.	2.0	9
331	Binding of ansa- and non-ansa-titanocene anticancer drugs to DNA: a DFT study. <i>Structural Chemistry</i> , 2010, 21, 735-744.	1.0	6

#	ARTICLE	IF	CITATIONS
332	Fine tuning chemotherapy to match BRCA1 status. <i>Biochemical Pharmacology</i> , 2010, 80, 647-653.	2.0	14
333	<i>In vitro</i> antitumor activity of titanocene alanine complex and its interaction with nucleic acids. <i>Chinese Journal of Chemistry</i> , 1997, 15, 225-233.	2.6	0
334	Biodegradable polymeric nanoparticles based drug delivery systems. <i>Colloids and Surfaces B: Biointerfaces</i> , 2010, 75, 1-18.	2.5	2,968
335	Cellular Responses to Cisplatin-Induced DNA Damage. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-16.	0.8	361
336	Comparison of the cytotoxic effects of <i>Juniperus sabina</i> and <i>Zataria multiflora</i> extracts with <i>Taxus baccata</i> extract and Cisplatin on normal and cancer cell lines. <i>Pharmacognosy Magazine</i> , 2010, 6, 102.	0.3	18
337	Poly(amidoamine) dendrimer-supported organoplatinum antitumour agents. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2010, 466, 1515-1526.	1.0	24
338	Effects of <i>Aulosira fertilissima</i> against Cisplatin-Induced Nephrotoxicity and Oxidative Stress in Rats. <i>Renal Failure</i> , 2010, 32, 224-233.	0.8	11
339	Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamate Complexes. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 283-292.	0.9	72
340	Structural and biochemical changes in mitochondria after cisplatin treatment of Dalton's lymphoma-bearing mice. <i>Mitochondrion</i> , 2010, 10, 38-45.	1.6	19
341	Polymer/Dendrimer Supported Organoplatinum Drugs. <i>ACS Symposium Series</i> , 2010, , 161-179.	0.5	0
342	Reduction of Cisplatin-Induced Nephrotoxicity in Vivo by Selenomethionine: The Effect on Cisplatin-DNA Adducts. <i>Chemical Research in Toxicology</i> , 2011, 24, 896-904.	1.7	27
343	Notice of Retraction: The Protective Effects of Pyrrolidine Dithiocarbamate on Cisplatin-Induced Nephrotoxicity in Mice. , 2011, , .		0
344	Remarks in Successful Cellular Investigations for Fighting Breast Cancer Using Novel Synthetic Compounds. , 0, , .		4
345	Amelioration of cisplatin-induced nephrotoxicity in mice by oral administration of diphenylmethyl selenocyanate. <i>Free Radical Research</i> , 2011, 45, 177-187.	1.5	26
346	PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 170-183.	6.6	908
347	Antitumor activity of bent metallocenes: electronic structure analysis using DFT computations. <i>Journal of Molecular Modeling</i> , 2011, 17, 465-475.	0.8	16
348	Gold(III)-dithiocarbamate anticancer agents: Activity, toxicology and histopathological studies in rodents. <i>International Journal of Cancer</i> , 2011, 129, 487-496.	2.3	92
349	Synthesis and enantiopreferential DNA-binding profile of late 3d transition metal <i>R</i> - and <i>S</i> -enantiomeric complexes derived from <i>N,N</i> -bis(1-benzyl-2-ethoxyethane): Validation of <i>R</i> -enantiomer of copper(II) complex as a human topoisomerase II inhibitor. <i>Chirality</i> , 2011, 23, 557-567.	1.3	18

#	ARTICLE	IF	CITATIONS
350	Spectroscopic studies of interactions of chondroitin sulfates with cisplatin. Carbohydrate Research, 2011, 346, 631-637.	1.1	6
351	Biochemical and ultrastructural studies on the protective effect of ginger extract against cisplatin-induced hepatotoxicity in adult male albino rats. Egyptian Journal of Histology, 2011, 34, 231-238.	0.0	4
352	PREPARATION OF CISPLATIN COMPOSITE MICRO/NANOFIBERS AND ANTITUMOR ACTIVITY <i>IN VITRO</i> AGAINST HUMAN TUMOR spc-a-1 CELLS. Nano, 2011, 06, 325-332.	0.5	17
353	How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment. Current Medicinal Chemistry, 2012, 19, 1870-1888.	1.2	10
354	Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives of Toxicology, 2012, 86, 1233-1250.	1.9	298
355	Induction of DNA fragmentation, chromosome aberrations and micronuclei by cisplatin in rat bone-marrow cells: Protective effect of recombinant human erythropoietin. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 747, 202-206.	0.9	20
356	Systematic differences in electrochemical reduction of the structurally characterized anti-cancer platinum(IV) complexes [Pt{((p- HC_6F_4)NCH $_2$) $_2$ -(pyridine) $_2$ Cl $_2$], [Pt{((p- HC_6F_4)NCH $_2$) $_2$ -(pyridine) $_2$ (OH) $_2$], and [Pt{((p- HC_6F_4)NCH $_2$) $_2$ -(pyridine) $_2$ (OH)Cl]. Journal of Inorganic Biochemistry, 2012, 115, 226-239.	1.5	32
357	Decursin Mediated Protection on Cisplatin-induced Nephrotoxicity in SD Rats and BDF1 Mice. The Journal of Northeast Agricultural University, 2012, 19, 50-56.	0.1	1
358	Screen of FDA-approved drug library reveals compounds that protect hair cells from aminoglycosides and cisplatin. Hearing Research, 2012, 294, 153-165.	0.9	68
359	Oxidative Stress in Cancer Biology and Therapy. , 2012, , .		5
360	Neural network assessment of herbal protection against chemotherapeutic-induced reproductive toxicity. Theoretical Biology and Medical Modelling, 2012, 9, 1.	2.1	22
361	Studies on the protective effect of flaxseed oil on cisplatin-induced hepatotoxicity. Human and Experimental Toxicology, 2012, 31, 364-375.	1.1	44
362	Antioxidants and Inhibition of Cisplatin-Induced Kidney Injury: Role of Mitochondria. , 2012, , 407-425.		2
363	Ameliorative influence of <i>Urtica dioica</i> L. against cisplatin-induced toxicity in mice bearing Ehrlich ascites carcinoma. Drug and Chemical Toxicology, 2012, 35, 251-257.	1.2	29
364	Protective effects of 6-hydroxy-1-methylindole-3-acetonitrile on cisplatin-induced oxidative nephrotoxicity via Nrf2 inactivation. Food and Chemical Toxicology, 2013, 62, 159-166.	1.8	14
365	Molsidomine Prevents Cisplatin-induced Hepatotoxicity. Archives of Medical Research, 2013, 44, 521-528.	1.5	54
366	Post-Transcriptional Controls by Ribonucleoprotein Complexes in the Acquisition of Drug Resistance. International Journal of Molecular Sciences, 2013, 14, 17204-17220.	1.8	19
367	Cisplatin and dietary ascorbic acid mediated changes in the mitochondria of Dalton's lymphoma-bearing mice. Fundamental and Clinical Pharmacology, 2013, 27, 329-338.	1.0	6

#	ARTICLE	IF	CITATIONS
368	Suppression of Chloride Channel 3 Expression Facilitates Sensitivity of Human Glioma U251 Cells to Cisplatin Through Concomitant Inhibition of Akt and Autophagy. <i>Anatomical Record</i> , 2013, 296, 595-603.	0.8	43
369	Production of high specific activity ^{195m} Pt cisplatin at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 495-503.	0.5	11
370	Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. <i>British Journal of Cancer</i> , 2013, 108, 859-865.	2.9	14
371	Detection of DNA crosslinks in peripheral lymphocytes isolated from patients treated with platinum derivatives using modified comet assay. <i>Neoplasma</i> , 2013, 60, 413-418.	0.7	15
372	Vitamin E Is a Nephroprotectant Agent in Male but Not in Female in a Model of Cisplatin-Induced Nephrotoxicity. <i>ISRN Nephrology</i> , 2013, 2013, 1-6.	1.2	20
373	Effect of cisplatin on glutathione redox status in isolated plasma and cytosolic fraction. <i>African Journal of Pharmacy and Pharmacology</i> , 2013, 7, 37-45.	0.2	1
374	Pre-treatment with glutamine reduces genetic damage due to cancer treatment with cisplatin. <i>Genetics and Molecular Research</i> , 2013, 12, 6040-6051.	0.3	10
375	Biodistribution and dosimetry of ^{195m} Pt-cisplatin in normal volunteers. <i>Nuklearmedizin - Nuclear Medicine</i> , 2013, 52, 222-227.	0.3	19
376	Role of the DNA Base Excision Repair Protein, APE1 in Cisplatin, Oxaliplatin, or Carboplatin Induced Sensory Neuropathy. <i>PLoS ONE</i> , 2014, 9, e106485.	1.1	88
377	JWA reverses cisplatin resistance via the CK2 α XRCC1 pathway in human gastric cancer cells. <i>Cell Death and Disease</i> , 2014, 5, e1551-e1551.	2.7	52
378	Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes. <i>Cancer Research</i> , 2014, 74, 3913-3922.	0.4	277
379	Development of a dual-functional Pt ^{II} -Fe-HAP magnetic nanoparticles application for chemo-hyperthermia treatment of cancer. <i>Ceramics International</i> , 2014, 40, 5117-5127.	2.3	40
380	Vitamin C Protects Against Cisplatin-Induced Nephrotoxicity and Damage Without Reducing Its Effectiveness in C57BL/6 Mice Xenografted With Lewis Lung Carcinoma. <i>Nutrition and Cancer</i> , 2014, 66, 1085-1091.	0.9	30
381	POLYMERIC NANOPARTICLE MEDIATED TARGETED DRUG DELIVERY TO CANCER CELLS. , 2014, , 1-34.		4
382	DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives. <i>Oncology Reports</i> , 2014, 31, 391-396.	1.2	22
383	Enzyme α -Instructed Intracellular Molecular Self α -Assembly to Boost Activity of Cisplatin against Drug α -Resistant Ovarian Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 13307-13311.	7.2	158
384	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 501-519.	1.5	3
385	Effect of diabetes on biodistribution, nephrotoxicity and antitumor activity of cisplatin in mice. <i>Chemico-Biological Interactions</i> , 2015, 229, 119-131.	1.7	19

#	ARTICLE	IF	CITATIONS
386	Cisplatin-induced testicular dysfunction and its amelioration by <i>Launaea taraxacifolia</i> leaf extract. <i>Andrologia</i> , 2015, 47, 553-559.	1.0	22
387	The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity. <i>Renal Failure</i> , 2015, 37, 332-336.	0.8	83
388	Biochemical changes associated with ascorbic acid-cisplatin combination therapeutic efficacy and protective effect on cisplatin-induced toxicity in tumor-bearing mice. <i>Toxicology Reports</i> , 2015, 2, 489-503.	1.6	21
389	Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2015, 44, 1-10.	1.9	39
390	Reduced toxicological manifestations of cisplatin following encapsulation in folate grafted albumin nanoparticles. <i>Life Sciences</i> , 2015, 142, 76-85.	2.0	19
392	APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 779, 96-104.	0.4	31
393	Pharmacokinetics of cisplatin in the absence or presence of Zengmian Yiliu granules (a traditional) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 interactions. <i>Pharmaceutical Biology</i> , 2015, 53, 159-166.	1.3	11
394	Morin Hydrate Mitigates Cisplatin-Induced Renal and Hepatic Injury by Impeding Oxidative/Nitrosative Stress and Inflammation in Mice. <i>Journal of Biochemical and Molecular Toxicology</i> , 2016, 30, 571-579.	1.4	21
395	Kinetics and thermochemistry of hydrolysis mechanism of a novel anticancer agent trans-[PtCl ₂ (dimethylamine)(isopropylamine)]: A DFT study. <i>Chemical Physics Letters</i> , 2016, 651, 216-220.	1.2	1
396	Improved efficacy of cisplatin in combination with a nano-formulation of pentacyclic triterpenediol. <i>Materials Science and Engineering C</i> , 2016, 68, 109-116.	3.8	19
397	Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 56-70.	1.5	69
398	Polyester Carriers for Enzyme Delivery. , 2016, , 675-707.		0
399	Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 159-169.	1.5	18
400	Biodegradable Nanoparticles and Their In Vivo Fate. , 2016, , 21-39.		1
401	Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 225-232.	2.9	37
402	Metal Based Compounds, Modulators of Na, K-ATPase with Anticancer Activity. , 2016, , 389-425.		1
403	Near infrared BODIPY-Platinum conjugates for imaging, photodynamic therapy and chemotherapy. <i>Dyes and Pigments</i> , 2017, 141, 5-12.	2.0	40
404	Ameliorative effects of pine bark extract on cisplatin-induced acute kidney injury in rats. <i>Renal Failure</i> , 2017, 39, 363-371.	0.8	16

#	ARTICLE	IF	CITATIONS
405	Mechanistic study of the substitution reactions of [Pt(II)(bis(2-pyridylmethyl)amine)H ₂ O](ClO ₄) ₂ and [Pt(II)(bis(2-pyridylmethyl)sulfide)H ₂ O](ClO ₄) ₂ with azole Nucleophiles. Crystal structure of [Pt(II)(bis(2-pyridylmethyl)sulfide)Cl]ClO ₄ . <i>Inorganica Chimica Acta</i> , 2017, 466, 298-307.	1.2	3
406	Beyond chemotherapeutics: cisplatin as a temporary buckle to fabricate drug-loaded nanogels. <i>Chemical Communications</i> , 2017, 53, 779-782.	2.2	25
407	Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line. <i>Food and Chemical Toxicology</i> , 2017, 109, 143-154.	1.8	23
408	Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies. <i>Journal of Inorganic Biochemistry</i> , 2017, 166, 76.	1.5	4
409	Polymeric Nanoparticles in Targeting and Delivery of Drugs. , 2017, , 223-255.		12
410	Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line. <i>Oncology Reports</i> , 2017, 37, 2366-2374.	1.2	2
411	MiRNAs in Cervical Cancer Radio- and Chemotherapy Response. , 2017, , .		2
412	Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding. <i>Renal Failure</i> , 2018, 40, 314-322.	0.8	56
413	A review of recent progress in drug and protein encapsulation: Approaches, applications and challenges. <i>Materials Science and Engineering C</i> , 2018, 83, 233-246.	3.8	80
414	A β -carboline derivative-based nickel(II) complex as a potential antitumor agent: synthesis, characterization, and cytotoxicity. <i>MedChemComm</i> , 2018, 9, 100-107.	3.5	11
415	ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum(II) complexes. <i>Analyst</i> , 2018, 143, 6087-6094.	1.7	19
416	Metallothionein: An Aggressive Scavenger – The Metabolism of Rhodium(II) Tetraacetate (Rh ₂ (CH ₃ CO) ₄). <i>ACS Omega</i> , 2018, 3, 16314-16327.	1.6	18
417	Renoprotective effect of the isoflavonoid biochanin A against cisplatin induced acute kidney injury in mice: Effect on inflammatory burden and p53 apoptosis. <i>International Immunopharmacology</i> , 2018, 61, 8-19.	1.7	36
418	Suppression of chloride voltage-gated channel 3 expression increases sensitivity of human glioma U251 cells to cisplatin through lysosomal dysfunction. <i>Oncology Letters</i> , 2018, 16, 835-842.	0.8	7
419	Barium ion cross-linked alginate-carboxymethyl cellulose composites for controlled release of anticancer drug methotrexate. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 54, 101324.	1.4	21
420	Oxidative DNA Cleavage, Formation of \cdot OH, \cdot NO ₂ and \cdot NO ₃ Species, and Cytotoxicity of Dicopper(II) Complex Supported by a <i>p</i> -Cresol-Derived Amide-Tether Ligand. <i>Inorganic Chemistry</i> , 2019, 58, 14294-14298.	1.9	10
421	Protective Effects of Serotonin and its Derivatives, <i>N</i> -Feruloylserotonin and <i>N</i> -(<i>p</i> -Coumaroyl) Serotonin, Against Cisplatin-Induced Renal Damage in Mice. <i>The American Journal of Chinese Medicine</i> , 2019, 47, 369-383.	1.5	10
422	Accurate quantification of carboplatin adducts with serum proteins by monolithic chromatography coupled to ICPMS with isotope dilution analysis. <i>Journal of Analytical Atomic Spectrometry</i> , 2019, 34, 729-740.	1.6	12

#	ARTICLE	IF	CITATIONS
423	Cyclometallated platinum(IV) compounds as promising antitumour agents. <i>Journal of Organometallic Chemistry</i> , 2019, 879, 15-26.	0.8	16
424	Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 240-249.	1.3	5
425	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
426	Interaction of CT-DNA with Ruthenium(II) Metallosurfactant Complexes: Synthesis, CMC Determination, Antitumour and Antimicrobial Activities. <i>Asian Journal of Chemistry</i> , 2020, 32, 665-677.	0.1	4
427	Quinoline-triazole half-sandwich iridium(III) complexes: synthesis, antiplasmodial activity and preliminary transfer hydrogenation studies. <i>Dalton Transactions</i> , 2020, 49, 11543-11555.	1.6	14
428	Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(II) complexes. <i>Dalton Transactions</i> , 2020, 49, 14009-14016.	1.6	10
429	Links between cancer metabolism and cisplatin resistance. <i>International Review of Cell and Molecular Biology</i> , 2020, 354, 107-164.	1.6	48
430	Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency <i>In Vivo</i> . <i>In Vivo</i> , 2021, 35, 779-791.	0.6	2
431	Subcellular Localisation of a Quinoline-Containing Fluorescent Cyclometallated Ir ^{III} Complex in <i>Plasmodium falciparum</i> . <i>ChemBioChem</i> , 2021, 22, 1568-1572.	1.3	4
432	Establishing an Interdisciplinary Oncology Team. , 2006, , 184-193.		1
433	Nanoscale Dendrimer-Platinum Conjugates as Multivalent Antitumor Drugs. , 2008, , 269-294.		5
434	New Platinum Drugs. , 1993, , 169-212.		7
435	Genetic Analysis of Cisplatin Resistance in Yeast and Mammals. , 2007, , 393-408.		1
436	Complexes of Water Soluble Polymers and Organoplatinum Compounds as Potential Time-Release Antitumor Formulations. , 1988, , 670-683.		2
437	Mechanisms of Cisplatin Resistance and Its Reversal In Human Tumors. , 1995, , 225-264.		6
438	Mechanisms for Cisplatin-FUra Synergism and Cisplatin Resistance in Human Ovarian Carcinoma Cells both in vitro and in vivo. <i>Advances in Experimental Medicine and Biology</i> , 1988, 244, 127-135.	0.8	20
439	Platinum Complexes. , 1997, , 93-112.		1
440	Development, Optimization and Characterization of Nanoparticle Drug Delivery System of Cisplatin. <i>IFMBE Proceedings</i> , 2009, , 1325-1328.	0.2	3

#	ARTICLE	IF	CITATIONS
441	Heavy Metal Neuropathies. , 1989, , 49-95.		1
442	The chemistry of platinum antitumour agents. , 1990, , 331-341.		3
443	Therapy of Metastasis in Animal Models. , 1989, , 192-200.		2
444	Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.. Journal of Biological Chemistry, 1990, 265, 11285-11288.	1.6	70
445	GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation.. Journal of Biological Chemistry, 1994, 269, 29085-29093.	1.6	182
446	Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance.. Journal of Biological Chemistry, 1993, 268, 20116-20125.	1.6	440
447	Dendrimer Porphyrin (Phthalocyanine). , 0, , 2350-2366.		1
448	Anticlastogenic effect of vitamin C on cisplatin in vivo. Genetics and Molecular Biology, 1999, 22, 415-417.	0.6	19
449	A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity. Current Genomics, 2016, 17, 279-293.	0.7	27
450	Alteration of oxidative stress parameters in red blood cells of rats after chronic in vivo treatment with cisplatin and selenium. Archives of Biological Sciences, 2011, 63, 991-999.	0.2	8
451	Mutation Spectra in Cisplatin- and Transplatin-treated GDL1 Cells Clarified the Different Mode of Action of These Compounds in Mammalian Cells. Genes and Environment, 2007, 29, 89-99.	0.9	3
452	Activation of Murine Peritoneal Macrophages with Cisplatin and Lipopolysaccharide: Involvement of Protein Kinase C and Tyrosine Kinase.. Journal of Clinical Biochemistry and Nutrition, 1994, 17, 55-64.	0.6	16
453	Ascorbic Acid (Vitamin C)-Mediated Protection on Mutagenic Potentials of Cisplatin in Mice Bearing Ascites Dalton $\hat{\text{A}}^{\text{TM}}$ s Lymphoma. Research Journal of Mutagenesis, 2016, 6, 1-21.	0.8	4
454	An $\hat{\text{i}}\hat{\text{g}}\hat{\text{t}}\hat{\text{i}}\hat{\text{n}}$ Vitro $\hat{\text{i}}\hat{\text{g}}\hat{\text{t}}\hat{\text{i}}$ Study on the Interactions of Pycnogenol $\hat{\text{A}}^{\text{TM}}$ with Cisplatin in Human Cervical Cancer Cells. Turkish Journal of Pharmaceutical Sciences, 2020, 17, 1-6.	0.6	8
455	Comparison of different sample preparation methods for platinum determination in cultured cells by graphite furnace atomic absorption spectrometry. PeerJ, 2017, 5, e2873.	0.9	7
456	Possible Protective Effects of Garlic, Ginkobiloba and Silymarin on Cisplatin Hepatotoxicity in Protein-Malnourished Rats. British Journal of Medicine and Medical Research, 2014, 4, 5398-5414.	0.2	2
457	Pharmacology of Anticancer Drugs. , 2000, , 168-186.		0
458	Relationship of Glutathion Concentrations with Cytotoxicity of Cisplatin in Different Cell Lines after Confront Vitamin C and E.. Pakistan Journal of Biological Sciences, 2006, 9, 2734-2742.	0.2	1

#	ARTICLE	IF	CITATIONS
460	Les traitements gÃ©nÃ©raux. , 2011, , 125-160.		0
461	Dietary Ascorbic Acid-Mediated Augmentation of Antitumor Activity and Protection Against Toxicities Induced by Cis- Diamminedichloroplatinum-(II) in Daltonâ€™s Lymphoma-Bearing Mice. Journal of Cancer Research Updates, 0, , .	0.3	0
462	Synthesis, characterization, DNA binding and anticancer property of mer-trichlorodimethylsulphoxide-S-(1, 10- phenanthroline) ruthenium (III). IOSR Journal of Applied Chemistry, 2014, 7, 71-80.	0.2	0
463	VERAPAMIL ENHANCEMENT OF THE ANTITUMOR EFFECT AND CYTOTOXICITY OF CIS-DIAMMINEDICHLOROPLATINUM (II) IN HUMAN NEUROBLASTOMA. The KITAKANTO Medical Journal, 1987, 37, 493-503.	0.0	0
464	Mechanisms of Neurotoxicity and Experimental Models. , 1990, , 25-43.		0
465	Circumvention of the resistance to cisplatin by hyperthermia on tumor cells.. Nihon Koku Geka Gakkai Zasshi, 1991, 37, 1217-1233.	0.0	0
466	Cross-Resistance to UV Radiation of a Cisplatin-Resistant Human Cell Line: Overexpression of Cellular Factors That Recognize UV-Modified DNA. Molecular and Cellular Biology, 1991, 11, 2075-2080.	1.1	18
467	Current Strategies in Anticancer Drug Discovery Within the EORTC. , 1992, , 93-103.		0
469	Treatment of ovarian cancer: the state of the art. Medical Oncology and Tumor Pharmacotherapy, 1993, 10, 139-42.	1.0	0
470	Role of Calcium/Calmodulin in Cisplatin-Induced Activation of Murine Bone Marrow-Derived Macrophages.. Journal of Clinical Biochemistry and Nutrition, 1998, 24, 1-12.	0.6	0
471	Non-Curative Treatment for Head and Neck Cancer. Focus on Cancer, 1998, , 173-185.	0.1	0
472	Ototoxicidad, otoprotecciÃ³n, autodefensa y regeneraciÃ³n del oÃ­do interno. , 2014, , 191-208.		0
473	Synthesis, Characterization, and Evaluation of Antitumor Potential in MCF-7 Cells of Ruthenium-Derived Compounds. Advances in Biological Chemistry, 2020, 10, 86-98.	0.2	1
474	Pharmacologic Aspects of Lung Cancer Chemotherapy. Clinics in Chest Medicine, 1986, 7, 505-513.	0.8	1
475	In-vitro release study of Pt(II) and Fe(III) metallocefotaxime drug candidates in pH dependent releasing mediums mimicking human biological fluids. Journal of Drug Delivery Science and Technology, 2022, , 103328.	1.4	1
476	A thiomethyl-substituted imidazolyl imine functionalized copper(II) complex: synthesis, structural characterization, phenoxazinone synthase mimics and biological activities. Polyhedron, 2022, 218, 115783.	1.0	1
477	Comprehensive comparison of theranostic nanoparticles in breast cancer.. American Journal of Clinical and Experimental Immunology, 2022, 11, 1-27.	0.2	0
479	PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open, 2022, 8, .	0.4	26

#	ARTICLE	IF	CITATIONS
480	A hemilabile 2-(2-pyridyl)-imidazole based nickel(II) complex: proton-coupled-electron-transfer, bactericidal and cytotoxicity studies. <i>New Journal of Chemistry</i> , 2022, 46, 17517-17526.	1.4	4
481	Vitamin C (Ascorbic acid) protects from neuropathy caused by cisplatin, through enhanced heat shock protein-70 and reduced oxidant effect. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1017-1022.	0.3	2
482	Synthesis and comparative evaluation of the cytotoxic activity of cationic organometallic complexes of the type $[Pt(\eta^1\text{-CH}_2\text{-CH}_2\text{-OR})(\text{DMSO})(\text{phen})]^+$ ($R = \text{Me, Et, Pr, Bu}$). <i>Inorganica Chimica Acta</i> , 2023, 546, 121321.	1.2	5
483	Development of Mitochondria Targeting Active Cyclometalated Iridium Complexes as Potent Antimalarial Agents. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	3
484	The Role of Metallodrugs in Cellular Senescence. <i>European Journal of Inorganic Chemistry</i> , 0, , .	1.0	0